Pharmaceutical Business Review
Drug Discovery & Development
Anonymous User | Login

Pfizer Q4 Net Income Increases 188%

Published: 04-Feb-2010

Pfizer has reported financial results for fourth-quarter and full-year 2009. Fourth-quarter 2009 revenues were $16.5 billion, an increase of 34% compared to $12.3 billion in the year-ago quarter. For full-year 2009, revenues were $50 billion, an increase of 4% compared to $48.3 billion in the same period in 2008.

For Q4 2009, Pfizer posted net income of $767m, an increase of 188% compared to $266m in the prior-year quarter, and reported diluted EPS of $0.10, an increase of 150% compared to $0.04 in the prior-year quarter.

For full-year 2009, the company reported net income of $8.6 billion, an increase of 7% compared to $8.1 billion last year, and posted diluted EPS of $1.23, an increase of 3% compared to $1.20 in 2008.

Jeff Kindler, chairman and chief executive officer of Pfizer, said: “During the fourth quarter, we closed the Wyeth acquisition and immediately began the integration of our operations, advancing the transformation of the company. We are pleased with the rapid pace of the integration and our ability to quickly realize the benefits of our combined organization.

“Our results this quarter clearly demonstrate the ability of our colleagues to remain focused and deliver solid operational performance, while working to close the Wyeth acquisition and to ensure a successful integration. We remain excited about our more diverse in-line product and pipeline portfolio, which we expect will result in improved opportunities for the company in 2010 and beyond.”

Frank D’Amelio, chief financial officer of Pfizer, said: “Our 2010 financial guidance and 2012 financial targets balance the achievement of our projected cost reductions, including from the integration of Wyeth, with the expected increased investment to drive longer-term, top and bottom line performance. These goals reflect our continued confidence in the business and our ability to capitalize on near- to mid-term growth opportunities through a meaningful reallocation of investment. Additionally, our 2012 targets assume a modest level of planned business-development activities.”

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Bioceros

Pre-Clinical Development of Monoclonal Antibodies and Generation of GMP-Ready Proteins ...

Bachem

Process Development and Manufacturing of Peptides and Complex Organic Molecules as APIs ...

NovAliX

Small Molecule Drug Discovery ...

Kuecept

Concept Formulation Design ...

Pharma IQ

Workshops, Conferences and Training Courses for Pharmaceutical Professionals ...

SGS

Life Science Services ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Your IP at Risk in Collaborations!

Free white paper: Ten steps to protect your R&D investment within partnerships. ...

Why, When and How to Conduct 14C Human Studies

Several risk-based strategies to assess metabolites exist. Whatever the strategy chosen, t ...

Why CAPA Still Matters

This free white paper explores the needs and effectiveness of correct CAPA control, how to ...

Water Treatment

From the control room to the downstream processing area and with an eye on utilities servi ...

Using the Mean Kinetic Temperature (MKT) As a Parameter to Determine Whether Perishable Goods Have Been Transported and Stored Correctly

Tecnosoft systems use MKT calculation to control the acquired values and report the user w ...

USB HotStart-IT for Real Time PCR

USB® Products from Affymetrix have a long-standing reputation in the life science marketpl ...

Related Companies

Pfizer Inc.

Pfizer Inc. (Pfizer) is a global research based pharmaceutical company principally focu ...

Merck & Co., Inc.

Merck & Co., Inc. (Merck) is a global research-driven pharmaceutical company engaged in ...

Merck KGaA

Merck KGaA (Merck) is a Germany-based company engaged in the manufacturing and distribu ...

Boehringer Ingelheim GmbH

Boehringer Ingelheim GmbH (Boehringer) is a group of companies engaged in the research, ...

Aurobindo Pharma Ltd

Aurobindo Pharma Limited (Aurobindo Pharma) is a pharmaceutical company. The company en ...

Suppliers Product News

mondoBIOTECH and Bachem Agree Long-Term Cooperation on the Development of Peptides to Fight Rare Diseases

mondoBIOTECH and Bachem on 24 September announced the conclusion of a longterm cooperation.

Novalyst Discovery and AliX Agree to Merge NovAliX Launch

Integrating structural biology and medicinal chemistry.

AliX and SOSHO to Sign Agreement for Protein Structure Determination of Intractable Targets

Breakthrough crystallisation technology for protein structure determination.

Kuecept and The School of Pharmacy Agree Key Drug Delivery Licensing

Kuecept Ltd and The School of Pharmacy, University of London agree key drug delivery licensing deals to facilitate the development of low solubility, poorly bioavailable compounds.

Synectix Pharmaceutical Solutions Now Called Kuecept

Synectix Pharmaceutical Solutions Ltd, the speciality drug development company, announced today that effective immediately, the company has changed its name to Kuecept Ltd.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address